{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:29:05Z","timestamp":1793143745666,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00292-025-01418-w","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:32:11Z","timestamp":1739871131000},"page":"90-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exanthematische Arzneimittelreaktionen","Exanthematic drug eruption"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-1917","authenticated-orcid":false,"given":"Mirjana","family":"Ziemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"e65284","key":"1418_CR1","first-page":"7","volume":"16","author":"P Dhage","year":"2024","unstructured":"Dhage\u00a0P et\u00a0al (2024) Prospective Analysis of Cutaneous Adverse Drug Reactions Encountered in a\u00a0Tertiary Care Hospital. Cureus 16(e65284):7","journal-title":"Cureus"},{"issue":"6","key":"1418_CR2","first-page":"765","volume":"137","author":"M Bigby","year":"2001","unstructured":"Bigby\u00a0M (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137(6):765\u2013770","journal-title":"Arch Dermatol"},{"issue":"2","key":"1418_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald\u00a0JB et\u00a0al (2015) Cutaneous adverse effects of targeted therapies: Part I:\u00a0Inhibitors of the cellular membrane. J\u00a0Am Acad Dermatol 72(2):203\u2013218","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1418_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/DAD.0b013e31820a285d","volume":"33","author":"M Naim","year":"2011","unstructured":"Naim\u00a0M, Weyers\u00a0W, Metze\u00a0D (2011) Histopathologic features of exanthematous drug eruptions of the macular and papular type. Am J Dermatopathol 33(7):695\u2013704","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"1418_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1046\/j.1365-2222.2000.00847.x","volume":"30","author":"N Yawalkar","year":"2000","unstructured":"Yawalkar\u00a0N et\u00a0al (2000) Infiltration of cytotoxic T\u00a0cells in drug-induced cutaneous eruptions. Clin Exp Allergy 30(6):847\u2013855","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"1418_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ddg.13876","volume":"17","author":"R Reschke","year":"2019","unstructured":"Reschke\u00a0R et\u00a0al (2019) Severe bullous skin eruptions on checkpoint inhibitor therapy\u2014in most cases severe bullous lichenoid drug eruptions. J\u00a0Dtsch Dermatol Ges 17(9):942\u2013948","journal-title":"J Dtsch Dermatol Ges"},{"key":"1418_CR7","first-page":"733","volume-title":"Fitzpatrick\u2019s Dermatology","author":"M Mockenhaupt","year":"2019","unstructured":"Mockenhaupt\u00a0M, Roujeau\u00a0J (2019) Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Kang\u00a0S et\u00a0al (Hrsg) Fitzpatrick\u2019s Dermatology. McGraw-Hill, New York, S\u00a0733\u2013748"},{"key":"1418_CR8","unstructured":"Ziemer M Lichenoid drug eruptions, drug induced lichen planus. 12.02.2024]; Ziemer M Lichenoid drug eruptions, drug induced lichen planus. In: UpToDate (ed). https:\/\/www.uptodate.com\/contents\/lichenoid-drug-eruption-drug-induced-lichen-planus. Zugegriffen: 6. Jan. 2025"},{"issue":"6","key":"1418_CR9","first-page":"777","volume":"20","author":"M Ziemer","year":"2022","unstructured":"Ziemer\u00a0M et\u00a0al (2022) Epidermale Nekrolyse im Zusammenhang mit immunonkologischen Medikamenten, Kinaseinhibitoren sowie Biologika. J\u00a0Dtsch Dermatol Ges 20(6):777\u2013787","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"1418_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","volume":"157","author":"A Sidoroff","year":"2007","unstructured":"Sidoroff\u00a0A et\u00a0al (2007) Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a\u00a0multinational case-control study (EuroSCAR). Br J Dermatol 157(5):989\u2013996","journal-title":"Br J Dermatol"},{"issue":"4","key":"1418_CR11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","volume":"139","author":"B Meier-Schiesser","year":"2019","unstructured":"Meier-Schiesser\u00a0B et\u00a0al (2019) Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis. J\u00a0Invest Dermatol 139(4):848\u2013858","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1418_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.15867","volume":"178","author":"R Mossner","year":"2018","unstructured":"Mossner\u00a0R et\u00a0al (2018) The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol 178(3):740\u2013748","journal-title":"Br J Dermatol"},{"issue":"6","key":"1418_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaad.2024.01.080","volume":"90","author":"M Yamanaka-Takaichi","year":"2024","unstructured":"Yamanaka-Takaichi\u00a0M et\u00a0al (2024) Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis. J\u00a0Am Acad Dermatol 90(6):1289\u20131291","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/jdv.18808","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin\u00a0K et\u00a0al (2023) Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases. J\u00a0Eur Acad Dermatol Venereol 37(4):753\u2013762","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun\u00a0SH et\u00a0al (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a\u00a0DRESS syndrome really exist? Br J Dermatol 156(3):609\u2013611","journal-title":"Br J Dermatol"},{"issue":"1","key":"1418_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/0378-6323.168934","volume":"82","author":"S Sasidharanpillai","year":"2016","unstructured":"Sasidharanpillai\u00a0S et\u00a0al (2016) Drug reaction with eosinophilia and systemic symptoms (DRESS): A\u00a0histopathology based analysis. Indian J Dermatol Venereol Leprol 82(1):28\u201336","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00105-013-2694-y","volume":"65","author":"M Mockenhaupt","year":"2014","unstructured":"Mockenhaupt\u00a0M (2014) Schwere arzneimittelinduzierte Hautreaktionen. Hautarzt 65:415\u2013423","journal-title":"Hautarzt"},{"issue":"3","key":"1418_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","volume":"70","author":"YT Cho","year":"2014","unstructured":"Cho\u00a0YT et\u00a0al (2014) Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features. J\u00a0Am Acad Dermatol 70(3):539\u2013548","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1418_CR19","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ddg.15516","volume":"22","author":"R Heuer","year":"2024","unstructured":"Heuer\u00a0R et\u00a0al (2024) S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)\u2014Part\u00a01: Diagnosis, initial management, and immunomodulating systemic therapy. J\u00a0Dtsch Dermatol Ges 22(11):1576\u20131593","journal-title":"J Dtsch Dermatol Ges"},{"key":"1418_CR20","doi-asserted-by":"crossref","unstructured":"Paulmann\u00a0M, Heuer\u00a0R, Annecke\u00a0T, Behr\u00a0B, Boch\u00a0K, Boos\u00a0AM, Brockow\u00a0K, French\u00a0LE, Gille\u00a0J, Gundlach\u00a0V, Hartmann\u00a0B, H\u00f6ger\u00a0P, Hofmann\u00a0SC, Klein\u00a0T, Lehnhardt\u00a0M, Li\u00df\u00a0Y, Maier\u00a0P, Mandel\u00a0P, Marathovouniotis\u00a0N, Marlok\u00a0F, Mittelviefhaus\u00a0H, Pleyer\u00a0U, Pradeau\u00a0M, Rall\u00a0K, Rieg\u00a0S, Rittner\u00a0H, Sander\u00a0F, Schnitzler\u00a0S, Schut\u00a0C, Stolle\u00a0A, Vorobyev\u00a0A, Wedi\u00a0B, Weiss\u00a0J, Zepp\u00a0M, Ziemer\u00a0M, Mockenhaupt\u00a0M, Nast\u00a0A (2024) S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) \u2013 Part\u00a02: Supportive therapy of EN in the acute and post-acute stages. J\u00a0Dtsch Dermatol Ges 22(11):1576\u20131593","DOI":"10.1111\/ddg.15516"},{"issue":"4","key":"1418_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clindermatol.2015.04.008","volume":"33","author":"R Wolf","year":"2015","unstructured":"Wolf\u00a0R, Tuzun\u00a0Y (2015) Baboon syndrome and toxic erythema of chemotherapy: Fold (intertriginous) dermatoses. Clin Dermatol 33(4):462\u2013465","journal-title":"Clin Dermatol"},{"key":"1418_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00105-013-2696-9","volume":"65","author":"M Ziemer","year":"2014","unstructured":"Ziemer\u00a0M (2014) Kutane Arzneimittelreaktionen vom Sp\u00e4ttyp. Pathogenese, Klinik und Histologie. Hautarzt 65:397\u2013408","journal-title":"Hautarzt"},{"issue":"12","key":"1418_CR23","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/cup.14090","volume":"48","author":"AM Schuler","year":"2021","unstructured":"Schuler\u00a0AM et\u00a0al (2021) Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19\u00a0cases and review of literature. J\u00a0Cutan Pathol 48(12):1471\u20131479","journal-title":"J Cutan Pathol"},{"issue":"5\u20136","key":"1418_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.0105-1873.2004.00445.x","volume":"51","author":"P Hausermann","year":"2004","unstructured":"Hausermann\u00a0P, Harr\u00a0T, Bircher\u00a0AJ (2004) Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Derm 51(5\u20136):297\u2013310","journal-title":"Contact Derm"},{"issue":"2","key":"1418_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/DAD.0000000000001722","volume":"43","author":"AM Muresan","year":"2021","unstructured":"Muresan\u00a0AM et\u00a0al (2021) Histopathological Spectrum and Immunophenotypic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema. Am J Dermatopathol 43(2):103\u2013111","journal-title":"Am J Dermatopathol"},{"issue":"15","key":"1418_CR26","doi-asserted-by":"publisher","first-page":"adv00224","DOI":"10.2340\/00015555-3457","volume":"100","author":"MJ Verheyden","year":"2020","unstructured":"Verheyden\u00a0MJ, Bilgic\u00a0A, Murrell\u00a0DF (2020) A\u00a0Systematic Review of Drug-Induced Pemphigoid. Acta Derm Venereol 100(15):adv224","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1418_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0923-1811(94)00371-K","volume":"9","author":"H Ogawa","year":"1995","unstructured":"Ogawa\u00a0H et\u00a0al (1995) The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J\u00a0Dermatol Sci 9(2):136\u2013141","journal-title":"J Dermatol Sci"},{"key":"1418_CR28","doi-asserted-by":"crossref","unstructured":"Kramer N et\u00a0al (2024) Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid. J\u00a0Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.19860"},{"issue":"6","key":"1418_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/bjd.21836","volume":"187","author":"A Kawsar","year":"2022","unstructured":"Kawsar\u00a0A et\u00a0al (2022) Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a\u00a0multicentre observational study. Br J Dermatol 187(6):981\u2013987","journal-title":"Br J Dermatol"},{"issue":"8","key":"1418_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","volume":"158","author":"MS Asdourian","year":"2022","unstructured":"Asdourian\u00a0MS et\u00a0al (2022) Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A\u00a0Systematic Review. JAMA Dermatol 158(8):933\u2013941","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1418_CR31","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1111\/jdv.17253","volume":"35","author":"C Juzot","year":"2021","unstructured":"Juzot\u00a0C et\u00a0al (2021) Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A\u00a0national retrospective study. J\u00a0Eur Acad Dermatol Venereol 35(8):e511\u2013e514","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1418_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/ijd.15627","volume":"60","author":"H Perandones-Gonzalez","year":"2021","unstructured":"Perandones-Gonzalez\u00a0H et\u00a0al (2021) Linear IgA\/IgG bullous dermatosis after nivolumab therapy. Int J Dermatol 60(8):1007\u20131009","journal-title":"Int J Dermatol"},{"key":"1418_CR33","volume-title":"Deutsche Krebsgesellschaft DK","author":"L Onkologie","year":"2020","unstructured":"Onkologie\u00a0L (2020) Supportive Therapie bei onkologischen PatientInnen \u2013 Langversion 1.3, 2020, AWMF Registernummer: 032\/054OL. In: AWMF (Hrsg) Deutsche Krebsgesellschaft DK"},{"issue":"10","key":"1418_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/cup.12202","volume":"40","author":"LA Brodell","year":"2013","unstructured":"Brodell\u00a0LA et\u00a0al (2013) Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J\u00a0Cutan Pathol 40(10):865\u2013870","journal-title":"J Cutan Pathol"},{"issue":"9","key":"1418_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim\u00a0YH et\u00a0al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T\u2011cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase\u00a03\u00a0trial. Lancet Oncol 19(9):1192\u20131204","journal-title":"Lancet Oncol"},{"issue":"6","key":"1418_CR36","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","volume":"157","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu\u00a0KE et\u00a0al (2021) Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome. JAMA Dermatol 157(6):700\u2013707","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1418_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","volume":"12","author":"ACM Musiek","year":"2022","unstructured":"Musiek\u00a0ACM et\u00a0al (2022) Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. Dermatol Ther (Heidelb) 12(1):29\u201340","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1418_CR38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","volume":"155","author":"L Chen","year":"2019","unstructured":"Chen\u00a0L et\u00a0al (2019) Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response. JAMA Dermatol 155(8):968\u2013971","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1418_CR39","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","volume":"44","author":"JY Wang","year":"2020","unstructured":"Wang\u00a0JY et\u00a0al (2020) Histopathologic Characterization of Mogamulizumab-associated Rash. Am J Surg Pathol 44(12):1666\u20131676","journal-title":"Am J Surg Pathol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01418-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:34:27Z","timestamp":1740461667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01418-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01418-w","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"13 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Ziemer und E.\u00a0Livingstone geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Alle Patient\/-innen, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}